Lontucirev
Alternative Names: CI 1042; DI 1520; ONYX-015Latest Information Update: 28 Nov 2005
Price :
$50 *
At a glance
- Originator Onyx Pharmaceuticals
- Developer Onyx Pharmaceuticals; Pfizer
- Class Antineoplastics; Oncolytic viruses
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Barrett's oesophagus; Cancer; Cancer metastases; Colorectal cancer; Head and neck cancer; Liver cancer; Oropharyngeal dysplasia; Ovarian cancer; Pancreatic cancer
Most Recent Events
- 23 Jun 2003 Discontinued - Phase-I for Barrett's oesophagus in USA (Intraluminal)
- 23 Jun 2003 Discontinued - Phase-I for Ovarian cancer in United Kingdom (Intraperitoneal)
- 23 Jun 2003 Discontinued - Phase-I for Ovarian cancer in USA (Intraperitoneal)